The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Association of Bariatric Surgery With Major Adverse Liver and Cardiovascular Outcomes in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis
Open accessAbstract
IMPORTANCE: No therapy has been shown to reduce the risk of serious adverse outcomes in patients with nonalcoholic steatohepatitis (NASH). OBJECTIVE: To investigate the long-term relationship between bariatric surgery and incident major adverse liver outcomes and major adverse cardiovascular events (MACE) in patients with obesity and biopsy-proven fibrotic NASH without cirrhosis. DESIGN, SETTING, AND PARTICIPANTS: In the SPLENDOR (Surgical Procedures and Long-term Effectiveness in NASH Disease and Obesity Risk) study, of 25 828 liver biopsies performed at a US health system between 2004 and 2016, 1158 adult patients with obesity were identified who fulfilled enrollment criteria, including confirmed histological diagnosis of NASH and presence of liver fibrosis (histological stages 1-3). Baseline clinical characteristics, histological disease activity, and fibrosis stage of patients who underwent simultaneous liver biopsy at the time of bariatric surgery were balanced with a nonsurgical control group using overlap weighting methods. Follow-up ended in March 2021. EXPOSURES: Bariatric surgery (Roux-en-Y gastric bypass, sleeve gastrectomy) vs nonsurgical care. MAIN OUTCOMES AND MEASURES: The primary outcomes were the incidence of major adverse liver outcomes (progression to clinical or histological cirrhosis, development of hepatocellular carcinoma, liver transplantation, or liver-related mortality) and MACE (a composite of coronary artery events, cerebrovascular events, heart failure, or cardiovascular death), estimated using the Firth penalized method in a multivariable-adjusted Cox regression analysis framework. RESULTS: A total of 1158 patients (740 [63.9%] women; median age, 49.8 years [IQR, 40.9-57.9 years], median body mass index, 44.1 [IQR, 39.4-51.4]), including 650 patients who underwent bariatric surgery and 508 patients in the nonsurgical control group, with a median follow-up of 7 years (IQR, 4-10 years) were analyzed. Distribution of baseline covariates, including histological severity of liver injury, was well-balanced after overlap weighting. At the end of the study period in the unweighted data set, 5 patients in the bariatric surgery group and 40 patients in the nonsurgical control group experienced major adverse liver outcomes, and 39 patients in the bariatric surgery group and 60 patients in the nonsurgical group experienced MACE. Among the patients analyzed with overlap weighting methods, the cumulative incidence of major adverse liver outcomes at 10 years was 2.3% (95% CI, 0%-4.6%) in the bariatric surgery group and 9.6% (95% CI, 6.1%-12.9%) in the nonsurgical group (adjusted absolute risk difference, 12.4% [95% CI, 5.7%-19.7%]; adjusted hazard ratio, 0.12 [95% CI, 0.02-0.63]; P = .01). The cumulative incidence of MACE at 10 years was 8.5% (95% CI, 5.5%-11.4%) in the bariatric surgery group and 15.7% (95% CI, 11.3%-19.8%) in the nonsurgical group (adjusted absolute risk difference, 13.9% [95% CI, 5.9%-21.9%]; adjusted hazard ratio, 0.30 [95% CI, 0.12-0.72]; P = .007). Within the first year after bariatric surgery, 4 patients (0.6%) died from surgical complications, including gastrointestinal leak (n = 2) and respiratory failure (n = 2). CONCLUSIONS AND RELEVANCE: Among patients with NASH and obesity, bariatric surgery, compared with nonsurgical management, was associated with a significantly lower risk of incident major adverse liver outcomes and MACE.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Long-term results of MBS consistently demonstrate safety and efficacy.”
From 2022 American Society of Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) Indications for Metabolic and Bariatric Surgery (2023) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, MBS is associated with an 88% risk reduction of progression of NASH to cirrhosis [18].”
From 2022 American Society of Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) Indications for Metabolic and Bariatric Surgery (2023) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Procedures like Roux-en-Y gastric bypass (RYGB) and vertical sleeve gastrectomy (VSG) are associated with significant metabolic improvements and reductions in NAFLD severity [13,14,15], including reductions in liver fat, liver enzymes, and fibrosis [16,17,18].”
From Impact of Bariatric Surgery and Endoscopic Therapies on Liver Health in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review (2025) · cites this paper as [17]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Notably, the 15 mg tirzepatide group in this trial exhibited an average weight decrease of 20.9%, and an impressive 36.2% of participants successfully achieved the≥25% weight-loss goal, approaching the effects observed with bariatric surgery [32, 33].”
The cited source says what the claim attributes to it.
In the citing paper
“After surgery, the significant improvement of metabolic disease, as well as the decrease in overall mortality, has been reported in multiple studies further supporting the importance of this treatment modality [15–19].”
The cited source says what the claim attributes to it.
In the citing paper
“Surgical, compared to non-surgical treatment, was related to reduce risk of major liver-related and cardiac events in patients with MASH and obesity [88].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [88]
The cited source says what the claim attributes to it.
In the citing paper
“In line with data from prospective studies, the large retrospective SPLENDOR study found signi fi cantly lower rates of adverse liver-related outcomes and major adverse cardiovascular events in individuals who underwent metabolic surgery compared to non-surgical controls.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [439]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“After surgery, the significant improvement of metabolic disease, as well as the decrease in overall mortality, has been reported in multiple studies further supporting the importance of this treatment modality [15–19].”
From 2022 American Society of Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) Indications for Metabolic and Bariatric Surgery (2023) · cites this paper as [18]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citationRUBIN, D. B. (1976) · Biometrika · doi:10.1093/biomet/63.3.581 · Cited by 9,925
Sensitivity analysis in observational research: Introducing the E-value
VanderWeele, T. J., & Ding, P. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2607 · Cited by 6,350
Austin, P. C. (2011) · Pharmaceutical Statistics · doi:10.1002/pst.433 · Cited by 3,949
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
Self-citationPioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Self-citationBariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes
Schauer, P. R., Bhatt, D. L., Kirwan, J. P., Wolski, K., Aminian, A., Brethauer, S. A., Navaneethan, S. D., Singh, R. P., Pothier, C. E., Nissen, S. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1600869 · Cited by 2,934
Self-citationMultiple imputation of discrete and continuous data by fully conditional specification
van Buuren, S. (2007) · Statistical Methods in Medical Research · doi:10.1177/0962280206074463 · Cited by 2,827
Non-alcoholic fatty liver disease
Powell, E. E., Wong, V. W.-S., & Rinella, M. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32511-3 · Cited by 2,789
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Self-citation
Cited by
Sorted by citations
Items 201–300 of 375
Ahmed, A. Y., Afifi, M., Arida, E. E., & Abdelhady, M. M. (2023) · Egyptian Journal of Anaesthesia · doi:10.1080/11101849.2023.2230047 · Cited by 4
Semaglutide for Metabolic Dysfunction–Associated Steatohepatitis
Simon, T. G. (2025) · New England Journal of Medicine · doi:10.1056/nejme2504717 · Cited by 4
Obesity and Cardiovascular Disease: Mechanistic Insights and Nutritional Management Strategies
Grossman, E. (2025) · Nutrients · doi:10.3390/nu17142281 · Cited by 6
Stupalkowska, W., Henney, A. E., Sheu, E. G., Alam, U., & Cuthbertson, D. J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70173 · Cited by 6
“13 Nevertheless, data on clinical outcomes in SLD patients after MBS are scarce and come mostly from observational analyses, likely due to the fact that these studies require a large number of patients with extensive follow-up.”
InfluentialMASLD and the cardiovascular-kidney-liver-metabolic syndrome
Angelidi, A. M., Boutari, C., Kokkorakis, M., Stefanakis, K., Mikhailidis, D. P., Jacob, G., & Mantzoros, C. S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag023 · Cited by 6
Kitsios, K., Trakatelli, C., Antza, C., Triantafyllou, Α., Sarigianni, M., & Kotsis, V. (2024) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2024.0059 · Cited by 3
Asada, T., Simon, C. Z., Durbas, A., Allen, M. R. J., DiSilvestro, K. J., Hirase, T., Singh, N., Bovonratwet, P., Heuer, A., Subramanian, T., et al. (2024) · The Spine Journal · doi:10.1016/j.spinee.2024.10.007 · Cited by 3
Dejeu, D., Dejeu, P., Muresan, A., Bradea, P., & Dejeu, V. (2024) · Medicina · doi:10.3390/medicina60122003 · Cited by 3
de BARROS, F., Guichardo, E. C., Fonseca, A. B. M., Pereira, L. H., & Encalada, D. (2025) · Obesity Surgery · doi:10.1007/s11695-025-08020-2 · Cited by 4
“These findings underscore the need for close postoperative monitoring of female patients with MASLD to prevent and manage biliary complications [25, 26].”
Gut microbiome and bile acid changes after male rodent sleeve gastrectomy: what comes first?
Welsch, E. C., Barron, M., Storage, K. M., Kazen, A. B., Aboulalazm, F. A., Kirby, J. R., & Kindel, T. L. (2025) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00297.2024 · Cited by 3
Bariatric Surgery - Past and Present
Kanat, B. H., Kutluer, N., & Doğan, S. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.100966 · Cited by 2
Song, Y., Guo, W., Liu, S., Li, Z., Guo, D. L., & Li, Y. (2022) · Obesity Surgery · doi:10.1007/s11695-022-06284-6 · Cited by 3
“Currently, bariatric surgery (BS) is generally considered to be a very effective treatment for hepatic steatosis [3, 4].”
BackgroundBariatric Surgery and Metabolic Dysfunction-Associated Fatty Liver Disease: a 2022 Update
Lazaridis, I. I., & Delko, T. (2023) · Praxis · doi:10.1024/1661-8157/a003969 · Cited by 3
Sleeve gastrectomy decreased hepatic lipid accumulation by inducing autophagy via AMPK/mTOR pathway
Zeng, R., Zeng, Y., Wang, Q., Li, X., Liu, J., Li, B., Zhang, G., & Hu, S. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.02.071 · Cited by 3
Jolfaei, A. G., Zahedi, Y., Pazouki, A., Nooraeen, S., & Pirhayati, M. (2023) · Current Psychosomatic Research · doi:10.32598/cpr.1.3.134.1 · Cited by 3
Ferretti, S. E., & Barreyro, F. J. (2024) · Current Hepatology Reports · doi:10.1007/s11901-023-00628-1 · Cited by 3
Lundholm, M. D., Kirschling, S., Hu, B., Aminian, A., Arterburn, D. E., Courcoulas, A. P., Cummings, D. E., GOURASH, W. F., Patti, M., Schauer, P. R., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15932 · Cited by 3
Self-citationOptimizing liver transplant candidacy in patients with cirrhosis and obesity
Ha, N. B., Heimbach, J. K., & Hameed, B. (2025) · Liver Transplantation · doi:10.1097/lvt.0000000000000609 · Cited by 3
Krishnan, A., Schneider, C. V., Mukherjee, D., Woreta, T. A., & Alqahtani, S. A. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01767-9 · Cited by 2
“There were significantly fewer major adverse liver outcomes and major adverse cardiovascular events associated with BS (adjusted absolute 10-year risk difference: 12.4% and 13.9%, respectively) [30].”
InfluentialOhnishi, Y., Yokote, T., Kawamitsu, K., Ogami, T., Nishimura, T., Uchida, T., & Kawakami, S. (2025) · Cureus · doi:10.7759/cureus.89977 · Cited by 2
“Overlapping populations have similar covariate distributions, ensuring clinical equality and eligibility for similar trials [27,28].”
InfluentialShah, A., Mohammadi, A., Haq, A., Walji, D., & Zevin, B. (2025) · Obesity Surgery · doi:10.1007/s11695-025-08246-0 · Cited by 3
“[ 15, 20] Lower serum levels of liver enzymes AST/ALT in patients with MASH after MBS may also suggest a reduction in hepatic inflammation.”
Li, C.-H., Huang, Y.-X., Duan, Y., Liu, G.-P., Ai, Z.-W., Ai, Z.-F., Li, J., & Li, S. (2025) · Food & Function · doi:10.1039/d5fo03892h · Cited by 2
Roles of Exosome–Derived Noncoding RNA in Fibrosis
Wang, Y., Le, Z., Shi, R., & Li, K. (2025) · Molecules and Cells · doi:10.1016/j.mocell.2025.100309 · Cited by 2
Management of obesity in advanced chronic liver disease
Caussy, C., & Francque, S. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.101749 · Cited by 2
“104 Interestingly, a long-term follow-up of a prospective cohort with biopsy-proven MASH and repeated liver biopsy at 1 year, not only confirmed the baseline prognostic value of MASH and fibrosis, but also demonstrated that histological remission of MASH or significant improvement of fibrosis from…”
Almazan, E., Choi, J., Kamath, T., Nguyen, V. H., Przybyszewski, E. M., Song, J., Carroll, A., Michta, M., Simon, T. G., & Chung, R. T. (2026) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000004048 · Cited by 2
Tuffs, C., Delistamatis, M., Hauenschild, A., Sauerbier, L., Amin, D., Kosovic, A., Amati, A., Albrecht, J. U., Askevold, I. H., Sprenger, T., et al. (2026) · Journal of Robotic Surgery · doi:10.1007/s11701-026-03462-x · Cited by 2
Wei, S., He, Y., Luo, C., & He, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1924392 · Cited by 4
“…NASH resolution and fi brosis regression (179), and is associated with a signi fi cantly reduced risk of adverse hepatic and cardiovascular outcomes (180); pioglitazone improves liver histology in NASH patients (181, 182); the GLP-1 receptor agonists liraglutide and semaglutide increased NASH…”
Schultes, B., & Ernst, B. (2023) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2023.06.004 · Cited by 2
Seidemann, L., & Dietrich, A. (2023) · Journal of Medical Case Reports · doi:10.1186/s13256-023-04111-9 · Cited by 2
“Several studies have shown that BS lowers the risk of HCC and other major adverse liver outcomes [15–17] and can lead to histological regression in metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis [18].”
BackgroundIndikation und präoperative Planung zur bariatrischen Operation
Felsenreich, D. M., Malzner, A., Eichner, M., Hoelbing, E., Moosbrugger, A., Beckerhinn, P., Prager, G., Brix, J. M., & Itariu, B.-K. (2023) · Wiener klinische Wochenschrift · doi:10.1007/s00508-023-02271-8 · Cited by 2
“Die Adipositaschirurgie führt zudem zu einer Reduktion des Progressionsrisikos von NASH zur Leberzirrhose um 88% [16].”
BackgroundEsparham, A., Shoar, S., Mehri, A., Khorgami, Z., & Modukuru, V. R. (2024) · Obesity Surgery · doi:10.1007/s11695-024-07238-w · Cited by 2
“…et al. found that in patients who suffer from both nonal-coholic steatohepatitis and obesity, MBS was found to be associated with a significantly reduced risk of major adverse liver outcomes and major adverse cardiovascular events when compared to those who underwent nonsurgical management [15].”
Wang, Z., Xu, G., Chen, G., Amin, B., Wang, L., Li, Z., Wang, J., Chen, W., Yu, C., Tian, C., et al. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s436176 · Cited by 2
“19 20–22 Shobini Jayaraman et al have shown that the modifications in low-density lipoprotein (LDL) play a pivotal role in the accelerated development of cardiovascular diseases (CVD) in obesity.”
BackgroundDetection of early-stage NASH using non-invasive hyperpolarized 13C metabolic imaging
von Morze, C., Blazey, T., Shaw, A., Spees, W. M., Shoghi, K. I., & Ohliger, M. A. (2024) · Scientific Reports · doi:10.1038/s41598-024-65951-z · Cited by 3
Clinical management of MASLD and MASH—An overview
Horn, P., & Newsome, P. N. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99649-5.00019-4 · Cited by 2
Storms, S., Oberhoff, G. H., Schooren, L., Kroh, A., Koch, A. H., Rheinwalt, K.-P., Vondran, F. W. R., Neumann, U. P., Alizai, P. H., & Schmitz, S. M. (2024) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2024.08.026 · Cited by 2
Mahjoubin‐Tehran, M., Atkin, S. L., Jamialahmadi, T., Kroh, M., Eid, A. H., Almahmeed, W. A., & Sahebkar, A. (2024) · Scientific Reports · doi:10.1038/s41598-024-70629-7 · Cited by 2
“This is seen from a clinical perspective with an improvement in diabetes 10,23 a reduction in cardiovascular events 24 and the long-term reduction in cancer incidence 25 .”
BackgroundDiabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease
Stefan, N., & Roden, M. (2024) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2312-0452 · Cited by 2
“In dieser Studie konnte bei Patienten mit MASH und Fettleibigkeit die bariatrische Chirurgie, im Vergleich mit einer nichtchirurgi-schen Behandlung, das Risiko für unerwünschte Leberschäden und schwere kardio-vaskuläre Ereignisse deutlich vermindern [20].”
Leite, A. R., Dias, J., Godinho, T., Correia-Chaves, J., Borges‐Canha, M., Lourenço, I. M., Leite-Moreira, A. F., & Neves, J. S. (2024) · Endocrinology Insights · doi:10.1159/000541442 · Cited by 3
“…seem to have signi fi cantly lower risk of long-term major adverse liver outcomes (cirrhosis, hepatocellular carcinoma, liver transplantation, or liver-related mortality) and major adverse cardiovascular events (coronary artery events, cerebrovascular events, HF, or cardiovascular death) [152].”
Ye, L., Yao, Z., Xuan, Q., Liu, Q., & Bo, T. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.151466 · Cited by 2
Lee, S., & Lee, M. (2025) · Studies in Nonlinear Dynamics and Econometrics · doi:10.1515/snde-2024-0125 · Cited by 10
“…gaining popularity in statistics, epidemiology, and medical science; see, e.g. Li et al. (2018),Mao et al. (2019),Li (2019),Zhou et al. (2020),Thomas et al. (2020),Aminian et al. (2021),Cheng et al. (2022), Anderson et al. (2023), Wei et al. (2023), Matsouaka and Zhou (2024), and Xu et al. (2025).”
Igwe, J., Surapaneni, P. K., Cruz, E. R., Cole, C., Njoku, K. K., Kim, J., Alaribe, U., Weze, K. O., & Mohammed, B. H. (2023) · Obesity Surgery · doi:10.1007/s11695-023-06833-7 · Cited by 2
“However, the lower odds of NASH/NAFLD among Hx-MBS compared to PR-MBS aligns well with recent research demonstrating lower incidence of major adverse liver outcomes for NAFLD patients receiving bariatric surgery compared to nonsurgical care [77].”
ResultOrekondy, N. S., Lee, D. J., & Malik, R. (2022) · Clinical Liver Disease · doi:10.1002/cld.1224 · Cited by 1
Pattou, F. N., Lassailly, G., Raverdy, V., Caiazzo, R. J., & Mathurin, P. (2022) · Hepatology · doi:10.1002/hep.32516 · Cited by 2
Zeng, J., & Fan, J.-G. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.1099 · Cited by 2
Dynamic Lipidomic Remodeling and Clinical Correlations after Sleeve Gastrectomy in Obese Subjects
Lee, G., Lee, Y. C., Park, M., Kim, S. M., Park, J.-H., & Lee, D. H. (2026) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0120 · Cited by 2
“While RYGB has superior weight loss effects, SG has become the most common bariatric surgery, with comparable long-term outcomes and notable metabolic benefits [2,3,5-8].”
Kwak, E. S., Alharbi, A., Bosaily, A. J. M., Alsughayer, A., Igbal, A., Salichs, O., Khuder, S., Fourman, M., & Assaly, R. (2025) · Hospital Practice · doi:10.1080/21548331.2025.2455921 · Cited by 1
“However, the advent of bariatric surgery as an effective treatment for obesity has raised questions about the implications of this intervention for patients with liver cirrhosis [7,8].”
Huynh, L., Kouzmina, E., Zevin, B., & Flemming, J. A. (2025) · Canadian Liver Journal · doi:10.3138/canlivj-2024-0015 · Cited by 1
Diagnose und Therapie der MASLD
Horn, P., & Tacke, F. (2025) · Die Innere Medizin · doi:10.1007/s00108-025-01896-3 · Cited by 1
Recent advances in anterior pituitary hormones and metabolic-associated fatty liver disease
Liu, C., Long, Y., Liu, J., & Song, Y. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1600559 · Cited by 1
Multidisciplinary clinical practice guideline on the management of metabolic hepatic steatosis
Romero‐Gómez, M., Escalada, J., Noguerol, M., Pérez, A., Carretero, J., Crespo, J., Mascort, J. J., Aguilar, I., Tinahones, F. J., Cañones, P., et al. (2025) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2025.502442 · Cited by 1
Progression of liver fibrosis after metabolic bariatric surgery in a MASLD rat model
Mairinger, M., Richwien, P., Eichelter, J., Mölzer, C., Jedamzik, J., Felsenreich, D. M., Sarocchi, F., Büchi, I., Wöran, K., Staufer, K., et al. (2025) · Clinical Nutrition · doi:10.1016/j.clnu.2025.07.019 · Cited by 1
Rizk, J. G. (2025) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2025.2546151 · Cited by 1
Rothberg, A. E., Ye, W., Miller, N., & Rizza, R. A. (2025) · Obesity Science & Practice · doi:10.1002/osp4.70092 · Cited by 1
“Bariatric surgery results in substantial and relatively durable weight loss and improvements in many of the metabolic and vascular complications of obesity [5–9].”
Impact of preoperative liver disease diagnosis on postoperative outcomes in bariatric surgery
Teklu, Y., Corpodean, F., Kachmar, M., Schauer, P. R., Cook, M. W., & Albaugh, V. L. (2025) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2025.10.006 · Cited by 1
Self-citationPeptide drugs for obesity and type 2 diabetes mellitus: an overview of clinical trials
Barzgar, H., Darmadi, D., Nafisa, J., Narkulov, S., & Sviridova, M. B. (2025) · Clinica Chimica Acta · doi:10.1016/j.cca.2025.120772 · Cited by 2
Sistanizad, M., Taherpour, N., Alibeigi, P., Sadeghi, S., Shamizadehkalkhoran, M., & Moradi, O. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-04524-4 · Cited by 1
“Fibrosis is the most important predictor of long-term liver-related morbidity and mortality in MAFLD and previously performed studies included this and demonstrated that bariatric surgery could improve fibrosis in this population [3].”
InfluentialA transdisciplinary framework for managing metabolic dysfunction associated steatotic liver disease
Kouser, S., Sharma, S. V., Bhanu, A., Kukkupuni, S. K., & Vishnuprasad, C. N. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1767844 · Cited by 2
“They often require multi-speciality care including hepatologists, endocrinologists, cardiologists, and dietitians (Fakhry et al., 2019; Lassailly et al., 2020; Aminian et al., 2021).”
Current management of MASLD in type 2 diabetes
Fernández‐Garibay, V. M., Sarabia-Chao, V., & Chávez-Tapia, N. C. (2026) · HORMONES · doi:10.1007/s42000-026-00763-6 · Cited by 1
Alzaki, A. A., Alqahtani, M., Aman, E., Asiri, G. M., Jibril, M. H. A., Desoky, R. M., Alqahtani, S. A., Suhaqi, L., Alkhalid, S. A., Alshareef, D. Y., et al. (2026) · Cureus · doi:10.7759/cureus.106038 · Cited by 2
“…incretin therapy (semaglutide/tirzepatide) to maximize the probability of NASH resolution, recognizing that durable ≥10% weight loss is a strong driver of histologic improvement and that surgical benchmarks (e.g., bariatric surgery) set the upper bound for weight-mediated regression [30-35].”
Metabolic dysfunction-associated steatotic liver disease in Asia: implications on management
Lai, K. N., & Wong, V. W. (2026) · Singapore Medical Journal · doi:10.4103/singaporemedj.smj-2025-167 · Cited by 1
Lifespan approaches for the prevention and management of steatotic liver disease
Zelber‐Sagi, S., Ivancovsky-Wajcman, D., Kugelmas, C., Weinstein, A. A., Wong, V. W., Castéra, L., Moore, J. B., Mouzaki, M., Hallsworth, K., Paik, J. M., et al. (2026) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-026-01198-5 · Cited by 1
“Retrospective cohort studies have shown that bariatric surgery also seems to reduce the risk of hepatic decompensation and HCC, even among patients with biopsy-proven compensated MASH cirrhosis 250,251 .”
Steatotic liver disease and cardiovascular-kidney-metabolic syndrome
Kolodziejczyk, H., & Ignatiev, E. (2026) · Nursing · doi:10.1097/nsg.0000000000000389 · Cited by 1
Papadia, F. S., Karcz, K. W., Pasta, A., & Giannini, E. (2026) · European Journal of Clinical Investigation · doi:10.1111/eci.70234 · Cited by 1
MASLD as Complication of Diabetes
Stefan, N. (2026) · Diabetes · doi:10.2337/dbi26-0001 · Cited by 1
Sebastian, R., Zevallos, A. S., Tuesta, O., Riva-Moscoso, A., Biller, J., Adrales, G. L., Li, C., & Schweitzer, M. (2026) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2026.06.001 · Cited by 1
ABDEEN, A. A., Ayer, T., Biswas, A., Wehrle, C. J., Laique, S. N., & Aminian, A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71020 · Cited by 1
“Metabolic and bariatric surgery (MBS) offers the greatest demonstrated reduction in MALO, liver transplantation, and mortality among patients with obesity and MASH [5, 6].”
Self-citationAnastomotic marginal ulceration after conversion of sleeve gastrectomy to Roux-en-Y gastric bypass
Ba’th, F., Feng, X., Gutnick, J., Augustin, T., Wilson, R. L., Dang, J. T., Strong, A. T., Cha, W., Bencsath, K. P., Tu, C., et al. (2026) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2026.08.007 · Cited by 1
Self-citationCurrent therapeutic landscape and future treatment perspectives of MASH
Gallage, S., Govaere, O., Anstee, Q. M., Shulman, G. I., Tacke, F., & Heikenwälder, M. F. (2026) · Nature · doi:10.1038/s41586-026-10672-8 · Cited by 4
“In cases of severe obesity, bariatric surgery is recommended based on improvement of histological and long-term outcome, mostly in patients who are non-cirrhotic 25,59 .”
InfluentialDavies, M. J., Aroda, V. R., Bajaj, M. S., ElSayed, N. A., Giorgino, F., Green, J., Kalyani, R. R., Maruthur, N. M., Mathieu, C., Rosas, S. E., et al. (2026) · Diabetologia · doi:10.1007/s00125-026-06855-7 · Cited by 1
Plauth, M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-98368-6.00004-5 · Cited by 1
Sleeve Gastrectomy Reduces Glycemia but Does Not Affect Cognitive Impairment in Lean 5xFAD Mice
Samuel, I., Schyr, R. B., Arad, Y., Attali, T., Azulai, S., Bergel, M., Halfon, A., Hefetz, L., Hirsh, T., Israeli, H., et al. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.937663 · Cited by 1
Stefan, N., & Roden, M. (2023) · Die Diabetologie · doi:10.1007/s11428-023-01038-z · Cited by 1
Pokhriyal, S. C., Nagpal, S., Gupta, U., Bhatt, P. K., Roy, P., Nway, N., Parkash, S., Yadav, R., & Deribe, Z. S. (2023) · Cureus · doi:10.7759/cureus.39544 · Cited by 1
“Bariatric surgery is considered superior to non-surgical treatment modalities like diet and exercise in the management of obese patients with NASH [1,9].”
BackgroundInfluentialEnfermedad por esteatohepatitis no alcohólica en pacientes diabéticos tipo 2: artículo de revisión
Miranda, G. (2023) · Horizonte Médico (Lima) · doi:10.24265/horizmed.2023.v23n2.13 · Cited by 1
NAFLD and type 2 diabetes: A practical guide for the joint management
Genua, I., Iruzubieta, P., Rodríguez-Duque, J. C., Pérez, A., & Crespo, J. (2023) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2022.12.010 · Cited by 1
Can Surgeons Reliably Identify Non-cirrhotic Liver Disease During Laparoscopic Bariatric Surgery?
Wuopio, A., Baker, B. M., Koethe, B. C., Goodman, M. D., Shin, R. D., Bugaev, N., Nepomnayshy, D., Kim, W. C., & Schnelldorfer, T. (2024) · Obesity Surgery · doi:10.1007/s11695-024-07070-2 · Cited by 1
Stefan, N., & Roden, M. (2024) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2166-6824 · Cited by 1
“In this study, bariatric surgery significantly reduced the risk of adverse liver damage and major cardiovascular events in pa - tients with NASH and obesity compared to nonsurgical treatment [20].”
BackgroundCambios en las recomendaciones de cirugía bariátrica metabólica
Martínez, W. A. R., Abreu-Lomba, A., Arias, R., & Vélez, J. P. (2024) · Interdisciplinary Journal of Epidemiology and Public Health · doi:10.18041/2665-427x/ijeph.1.10233
Surgical treatment of obesity for NAFLD
Goens, D., Johnson-Mann, C. N., Zarrinpar, A., & Patton, H. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99649-5.00015-7 · Cited by 1
Impact of Metabolic Surgery on Cardiovascular Disease Outcomes
Piché, M., Poirier, P., & Wong, J. A. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.05.013 · Cited by 2
Effect of Metabolic Surgery on Non-Alcoholic Steatohepatitis
Fearon, N. M., & Pournaras, D. J. (2023) · Springer eBooks · doi:10.1007/978-3-030-60596-4_107 · Cited by 1
Voies thérapeutiques dans l’hépatopathie stéatosique métabolique
Smati, S., Canivet, C. M., Boursier, J., & Cariou, B. (2023) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2023.03.007 · Cited by 1
Tacke, F., Roeb, E., & Canbay, A. E. (2022) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1899-9046 · Cited by 1
Romero-Gómez, M., Escalada, J., Noguerol, M., Pérez, A., Carretero, J., Crespo, J., Mascort, J. J., Aguilar, I., Tinahones, F., Cañones, P., et al. (2026) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2025.502639 · Cited by 1
Papadimopoulos, I., & Tacke, F. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70810 · Cited by 1
“…is now one of the most widely performed procedures worldwide, is significantly more effective than lifestyle modification or optimized medical obesity therapy in achieving MASH resolution and improving hepatic fibrosis as well as reducing long-term cardiovascular and hepatic complications [6, 7].”
MICROWAVE SPECTRUM AND STRUCTURE OF 2-CHLOROPROPIONITRILE
Ogata, T., & Yamashita, N. (1995) · The Knowledge Bank (The Ohio State University)
NASH y cirugía metabólica: cuando tienes los datos pero no puedes demostrarlo
Balibrea, J. M., & Turrado-Rodriguez, V. (2021) · Cirugía Española · doi:10.1016/j.ciresp.2021.11.016
Ratziu, V. (2022) · Hepatology · doi:10.1002/hep.32466
NASH/Adipositas: Bariatrische Chirurgie verringert unerwünschte Leberoutcomes
Lichert, F. (2022) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1711-9363
Metabolic surgery and NASH: When you have the data but you can’t prove it
Balibrea, J. M., & Turrado-Rodriguez, V. (2022) · Cirugía Española (English Edition) · doi:10.1016/j.cireng.2022.02.015
Ullah, A. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.105734
Impact of Metabolic and Bariatric Surgery on Liver Diseases
Agarwal, L., Chekuri, R., Singla, V., Kumar, A., Shalimar, S., & Aggarwal, S. (2022) · Journal of Bariatric Surgery · doi:10.4103/jbs.jbs_9_22
Stroh, C., & Luderer, D. (2022) · Allgemein- und Viszeralchirurgie up2date · doi:10.1055/a-1652-4605
Effect of Metabolic Surgery on Non-Alcoholic Steatohepatitis
Fearon, N. M., & Pournaras, D. J. (2022) · Springer eBooks · doi:10.1007/978-3-030-54064-7_107-1
Influence of fruit, meal distribution and dental health on cardio-metabolic risk
Ström, E. (2022) · Linköping University medical dissertations · doi:10.3384/9789179294489
Rapport 23-02. Le foie stéatosique non alcoolique : un défi de santé publique
Brissot, P., & Buffet, C. (2023) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2023.03.014
NASH et chirurgie de l’obésité
Leray, M., Lassailly, G., & Pattou, F. N. (2023) · Nutrition Clinique et Métabolisme · doi:10.1016/j.nupar.2022.12.002
Die nichtalkoholische Steatohepatitis (NASH) als Ursache erhöhter Leberwerte
Puengel, T., & Tacke, F. (2023) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1994-1722 · Cited by 1
“Beobachtungsstudien zeigen vorteilhafte Langzeiteffekte auf hepatische und extrahepatische Morbidität und Mortalität bei NAFLD durch eine Gewichtsreduktion, sowie einen verbesserten Metabolismus und sogar eine Reduktion der Leberfibrose [20].”
BackgroundStroh, C., & Luderer, D. (2023) · Diabetes aktuell · doi:10.1055/a-2116-9397
“Merke Verfahren mit duodenaler Exklusion wie der proximale Roux-en-Y-Magenbypass und der Single Anastomosis Gastric Bypass (MGB) weisen höhere Effekte auf die Remission des Diabetes mellitus Typ 2 und der nicht alkoholischen Fettleber auf als das rein restriktive Gastric Banding [9, 10].”
BackgroundInfluentialTratamiento farmacológico actual y futuro de la esteatosis hepática
Alonso, N., & Julián, M. T. (2023) · Diabetes práctica · doi:10.52102/diabet/pract.esteatosis.art7
Metadata
- Authors
- Aminian, A., Al-Kurd, A., Wilson, R., Bena, J., Fayazzadeh, H., Singh, T., Albaugh, V. L., Shariff, F. U., Rodriguez, N. A., Jin, J., Brethauer, S. A., Dasarathy, S., Alkhouri, N., Schauer, P. R., McCullough, A. J., & Nissen, S. E.
- Affiliations
- Cleveland Clinic (US)
- Bariatric and Metabolic Institute, Department of General Surgery, Cleveland Clinic, Cleveland, Ohio
- Pennington Biomedical Research Center (US)
- Corresponding author
- Nissen, Steven E.
- ORCID
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2021-11-23
- Volume
- 326
- Issue
- 20
- Pages
- 2031
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- PMC
- PMC8587225
- OpenAlex
- W3214171772
- Cited by
- 375
- References
- 36
- Citations by year
- 2026: 66 · 2025: 87 · 2024: 81 · 2023: 77 · 2022: 60 · 2021: 2
- FWCI
- 51.68
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (U01DK061732)
- Topics
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Surgery › Organ Transplantation Techniques and Outcomes
- Keywords
- bariatric surgery, nonalcoholic steatohepatitis, obesity, liver fibrosis, major adverse liver outcomes, major adverse cardiovascular events, Roux-en-Y gastric bypass, sleeve gastrectomy, cirrhosis progression, hepatocellular carcinoma, liver transplantation, cardiovascular mortality, liver-related mortality, long-term outcomes, overlap weighting
- MeSH terms
- Adult, Biopsy, Body Weight, Cardiovascular Diseases, Female, Carcinoma, Hepatocellular, Humans, Liver, Liver Cirrhosis, Liver Neoplasms, Male, Middle Aged, Obesity, Retrospective Studies, Incidence, Bariatric Surgery, Kaplan-Meier Estimate, Propensity Score, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
